Literature DB >> 23283601

Troponin elevation in subarachnoid hemorrhage does not impact in-hospital mortality.

Manisha Gupte1, Sayona John, Shyam Prabhakaran, Vivien H Lee.   

Abstract

BACKGROUND: Cardiac dysfunction is a well-known complication of subarachnoid hemorrhage (SAH). Our objective was to determine the frequency of troponin abnormalities in SAH and determine its impact on in-hospital mortality.
METHODS: With IRB approval, we retrospectively reviewed 225 consecutive SAH patients admitted to our institution from August 1, 2006 to June 1, 2009. Traumatic SAH patients were excluded. Data were collected on demographics, Hunt and Hess score (HH), in-hospital mortality, and peak troponin values on admission. CT images were independently reviewed and graded by the study neurologist for Fisher grade (FG) and the presence of intraventricular hemorrhage (IVH).
RESULTS: Among the 225 SAH patients, the mean age was 57.3 years (range, 21-90). The majority of patients were female (67%), FG 3 (75%), and had IVH (62%). Among the 201 patients with troponin I values, the mean troponin level was 0.93 (range, 0.01-25.8 ng/mL) and 47 (23%) had elevated troponin I levels. In unadjusted analysis, elevated troponin I level was significantly associated with in-hospital mortality. With multivariable logistic regression adjusting for age, HH, FG, and IVH, elevated troponin I level was no longer associated with in-hospital mortality (p. 0.34). In multivariate analysis, the independent predictors of in-mortality were age and severe grade HH (4-5).
CONCLUSIONS: Troponin I elevation after SAH is not an independent predictor of in-hospital mortality.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23283601     DOI: 10.1007/s12028-012-9813-y

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  22 in total

1.  An association between QTc prolongation and left ventricular hypokinesis during sequential episodes of subarachnoid hemorrhage.

Authors:  D Yoshikawa; T Hara; K Takahashi; T Morita; F Goto
Journal:  Anesth Analg       Date:  1999-10       Impact factor: 5.108

2.  Cardiac troponin I predicts myocardial dysfunction in aneurysmal subarachnoid hemorrhage.

Authors:  N Parekh; B Venkatesh; D Cross; A Leditschke; J Atherton; W Miles; A Winning; A Clague; C Rickard
Journal:  J Am Coll Cardiol       Date:  2000-10       Impact factor: 24.094

3.  Cardiac outcome in patients with subarachnoid hemorrhage and electrocardiographic abnormalities.

Authors:  J G Zaroff; G A Rordorf; J B Newell; C S Ogilvy; J R Levinson
Journal:  Neurosurgery       Date:  1999-01       Impact factor: 4.654

4.  An admission bioclinical score to predict 1-year outcomes in patients undergoing aneurysm coiling.

Authors:  Vincent Degos; Christian C Apfel; Paola Sanchez; Chantal Colonne; Isabelle Renuit; Frédéric Clarençon; Aurélien Nouet; Anne Laure Boch; Tony Pourmohamad; Helen Kim; Pierre Antoine Gourraud; William L Young; Louis Puybasset
Journal:  Stroke       Date:  2012-02-23       Impact factor: 7.914

5.  Serial electrocardiographic recording in aneurysmal subarachnoid hemorrhage.

Authors:  P J Brouwers; E F Wijdicks; D Hasan; M Vermeulen; E F Wever; H Frericks; J van Gijn
Journal:  Stroke       Date:  1989-09       Impact factor: 7.914

6.  Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia.

Authors:  M S Lüscher; K Thygesen; J Ravkilde; L Heickendorff
Journal:  Circulation       Date:  1997-10-21       Impact factor: 29.690

7.  A multiparameter panel method for outcome prediction following aneurysmal subarachnoid hemorrhage.

Authors:  Natacha Turck; Laszlo Vutskits; Paola Sanchez-Pena; Xavier Robin; Alexandre Hainard; Marianne Gex-Fabry; Catherine Fouda; Hadiji Bassem; Markus Mueller; Frédérique Lisacek; Louis Puybasset; Jean-Charles Sanchez
Journal:  Intensive Care Med       Date:  2009-09-17       Impact factor: 17.440

8.  Predictors of neurocardiogenic injury after subarachnoid hemorrhage.

Authors:  Poyee Tung; Alexander Kopelnik; Nader Banki; Ken Ong; Nerissa Ko; Michael T Lawton; Daryl Gress; Barbara Drew; Elyse Foster; William Parmley; Jonathan Zaroff
Journal:  Stroke       Date:  2004-01-22       Impact factor: 7.914

9.  Clinical significance of elevated troponin I levels in patients with nontraumatic subarachnoid hemorrhage.

Authors:  Ellen Deibert; Benico Barzilai; Alan C Braverman; Dorothy Farrar Edwards; Venkatesh Aiyagari; Ralph Dacey; Michael Diringer
Journal:  J Neurosurg       Date:  2003-04       Impact factor: 5.115

10.  Impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage: a meta-analysis.

Authors:  I A C van der Bilt; D Hasan; W P Vandertop; A A M Wilde; A Algra; F C Visser; G J E Rinkel
Journal:  Neurology       Date:  2009-02-17       Impact factor: 9.910

View more
  4 in total

1.  Relationship of Troponin T and Age- and Sex-Adjusted BNP Elevation Following Subarachnoid Hemorrhage with 30-Day Mortality.

Authors:  Katherine M Duello; Jay P Nagel; Colleen S Thomas; Joseph L Blackshear; William D Freeman
Journal:  Neurocrit Care       Date:  2015-08       Impact factor: 3.210

Review 2.  Impact of echocardiographic wall motion abnormality and cardiac biomarker elevation on outcome after subarachnoid hemorrhage: a meta-analysis.

Authors:  Limin Zhang; Bing Zhang; Sihua Qi
Journal:  Neurosurg Rev       Date:  2018-05-26       Impact factor: 3.042

3.  Cardiovascular Abnormalities and in-Hospital All-Cause Mortality in Patients with Spontaneous Sub-Arachnoid Hemorrhage: An Observational Study.

Authors:  Ahmed N Mahmoud; Akram Y Elgendy; Hend Mansoor; Islam Y Elgendy
Journal:  Cardiol Ther       Date:  2016-12-15

4.  Early and persistent high level of PS 100β is associated with increased poor neurological outcome in patients with SAH: is there a PS 100β threshold for SAH prognosis?

Authors:  Hervé Quintard; Sébastien Leduc; Patricia Ferrari; Isabelle Petit; Carole Ichai
Journal:  Crit Care       Date:  2016-02-03       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.